H3N2感染(H3N2 Infection)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
H3N2 Infection Overview 7
Therapeutics Development 8
Pipeline Products for H3N2 Infection – Overview 8
Pipeline Products for H3N2 Infection – Comparative Analysis 9
H3N2 Infection – Therapeutics under Development by Companies 10
H3N2 Infection – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
H3N2 Infection – Products under Development by Companies 14
H3N2 Infection – Companies Involved in Therapeutics Development 15
AlphaVax, Inc. 15
Colby Pharmaceutical Company 16
Crucell N.V. 17
Cure Lab, Inc. 18
Inovio Pharmaceuticals, Inc. 19
Johnson & Johnson 20
NanoViricides, Inc. 21
REPLICor Inc. 22
Takeda Pharmaceutical Company Limited 23
Vaxart, Inc. 24
H3N2 Infection – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Aspidasept – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AVX-502 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
bordetella pertussis [strain BPZE1] vaccine – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
C-05 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CLVax-1.0 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CR-9114 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Gamma-Flu – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ID-38 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
influenza [H3N2] vaccine – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
influenza vaccine – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
JVRS-100 + influenza [H1N1/H3N2] vaccine – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NVINF-1 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NVINF-2 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
REP-9 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
seasonal influenza [H3N2] vaccine – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
VX-787 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
H3N2 Infection – Recent Pipeline Updates 53
H3N2 Infection – Dormant Projects 59
H3N2 Infection – Product Development Milestones 60
Featured News & Press Releases 60
Oct 09, 2012: NanoViricides’s Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62